S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Aytu Biopharma Stock Forecast, Price & News

-0.05 (-2.70%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
428,322 shs
Average Volume
456,054 shs
Market Capitalization
$50.67 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AYTU News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Aytu Biopharma logo

About Aytu Biopharma

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.


Aytu Biopharma, Inc. (NASDAQ:AYTU) Short Interest Update
November 20, 2021 |  americanbankingnews.com
Aytu BioPharma Reports First Quarter 2022 Financial Results
November 15, 2021 |  finance.yahoo.com
Aytu Biopharma (AYTU) Scheduled to Post Earnings on Monday
November 10, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$65.63 million
Book Value
$3.96 per share


Net Income
$-58.29 million
Net Margins
Pretax Margin




Free Float
Market Cap
$50.67 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.73 out of 5 stars

Medical Sector

902nd out of 1,388 stocks

Pharmaceutical Preparations Industry

427th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Aytu Biopharma (NASDAQ:AYTU) Frequently Asked Questions

Is Aytu Biopharma a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aytu Biopharma stock.
View analyst ratings for Aytu Biopharma
or view top-rated stocks.

How has Aytu Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Aytu Biopharma's stock was trading at $1.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AYTU shares have increased by 33.3% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19

Are investors shorting Aytu Biopharma?

Aytu Biopharma saw a increase in short interest in October. As of October 29th, there was short interest totaling 1,930,000 shares, an increase of 31.3% from the October 14th total of 1,470,000 shares. Based on an average daily volume of 346,800 shares, the days-to-cover ratio is currently 5.6 days. Currently, 7.8% of the shares of the stock are short sold.
View Aytu Biopharma's Short Interest

When is Aytu Biopharma's next earnings date?

Aytu Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Aytu Biopharma

How were Aytu Biopharma's earnings last quarter?

Aytu Biopharma, Inc. (NASDAQ:AYTU) issued its quarterly earnings results on Monday, November, 15th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.60. Aytu Biopharma had a negative trailing twelve-month return on equity of 26.42% and a negative net margin of 110.57%. During the same period in the previous year, the business earned ($0.40) EPS.
View Aytu Biopharma's earnings history

When did Aytu Biopharma's stock split? How did Aytu Biopharma's stock split work?

Aytu Biopharma shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Biopharma stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for AYTU?

2 equities research analysts have issued 1 year target prices for Aytu Biopharma's stock. Their forecasts range from $11.00 to $14.50. On average, they anticipate Aytu Biopharma's share price to reach $12.75 in the next year. This suggests a possible upside of 608.3% from the stock's current price.
View analysts' price targets for Aytu Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Aytu Biopharma's key executives?

Aytu Biopharma's management team includes the following people:
  • Joshua R. Disbrow, Chairman & Chief Executive Officer
  • Jarrett T. Disbrow, Executive Vice President-Corporate Development
  • Richard I. Eisenstadt, Chief Financial Officer, Secretary & Treasurer
  • Russell Lee McMahen, Senior Vice President-Research & Development
  • Suzane Kennedy, VP-Regulatory Affairs & Quality Assurance

What other stocks do shareholders of Aytu Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu Biopharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

What is Aytu Biopharma's stock symbol?

Aytu Biopharma trades on the NASDAQ under the ticker symbol "AYTU."

Who are Aytu Biopharma's major shareholders?

Aytu Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.40%), BlackRock Inc. (1.81%), Morgan Stanley (1.37%), Millennium Management LLC (1.31%), Geode Capital Management LLC (0.93%) and Commonwealth Equity Services LLC (0.39%). Company insiders that own Aytu Biopharma stock include Armistice Capital Master Fund, Armistice Capital, Llc and Joshua R Disbrow.
View institutional ownership trends for Aytu Biopharma

Which institutional investors are selling Aytu Biopharma stock?

AYTU stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citadel Advisors LLC, Schonfeld Strategic Advisors LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Aytu Biopharma
or view top insider-selling stocks.

Which institutional investors are buying Aytu Biopharma stock?

AYTU stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Commonwealth Equity Services LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., BlackRock Inc., and Creative Planning. Company insiders that have bought Aytu Biopharma stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, and Joshua R Disbrow.
View insider buying and selling activity for Aytu Biopharma
or or view top insider-buying stocks.

How do I buy shares of Aytu Biopharma?

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aytu Biopharma's stock price today?

One share of AYTU stock can currently be purchased for approximately $1.80.

How much money does Aytu Biopharma make?

Aytu Biopharma has a market capitalization of $50.67 million and generates $65.63 million in revenue each year. The company earns $-58.29 million in net income (profit) each year or ($4.03) on an earnings per share basis.

How many employees does Aytu Biopharma have?

Aytu Biopharma employs 75 workers across the globe.

What is Aytu Biopharma's official website?

The official website for Aytu Biopharma is aytubio.com.

Where are Aytu Biopharma's headquarters?

Aytu Biopharma is headquartered at 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112.

How can I contact Aytu Biopharma?

Aytu Biopharma's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at (720) 437-6580 or via email at [email protected].

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.